Didanosine
Videx (didanosine) is a small molecule pharmaceutical. Didanosine was first approved as Videx on 1991-10-09. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Didanosine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIDEX | Bristol Myers Squibb | N-020156 DISCN | 1991-10-09 | 1 products, RLD |
| VIDEX | Bristol Myers Squibb | N-020154 DISCN | 1991-10-09 | 5 products, RLD |
| VIDEX | Bristol Myers Squibb | N-020155 DISCN | 1991-10-09 | 4 products |
| VIDEX EC | Bristol Myers Squibb | N-021183 DISCN | 2000-10-31 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| didanosine | ANDA | 2012-05-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0137 | Didanosine (ddi), 25 mg |
Clinical
Clinical Trials
135 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 29 | 49 | 21 | 7 | 26 | 130 |
| Hiv | D006678 | O98.7 | — | — | 1 | 1 | — | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | 1 | — | 1 | |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 2 | — | 1 | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 1 | — | 1 | 2 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kaposi sarcoma | D012514 | C46 | 1 | 1 | — | — | — | 2 | |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | 1 | — | — | 1 | 2 |
| Lymphoma | D008223 | C85.9 | — | 1 | — | — | — | 1 | |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | — | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | B19.2 | 1 | — | — | — | — | 1 | |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | 1 | — | — | — | — | 1 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | 1 | — | — | — | — | 1 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIDANOSINE |
| INN | didanosine |
| Description | Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS. It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1 |
Identifiers
| PDB | — |
| CAS-ID | 69655-05-6 |
| RxCUI | 3364 |
| ChEMBL ID | CHEMBL1460 |
| ChEBI ID | 490877 |
| PubChem CID | 50599 |
| DrugBank | DB00900 |
| UNII ID | K3GDH6OH08 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,058 documents
View more details
Safety
Black-box Warning
Black-box warning for: Didanosine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,863 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more